FMP
OKYO Pharma Limited
OKYO
NASDAQ
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
1.4 USD
0.05 (3.57%)
About
ceo
Dr. Gary S. Jacob Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.okyopharma.com
exchange
NASDAQ
Description
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
CIK
0001849296
ISIN
US6793451088
CUSIP
679345108
Address
55 Park Lane
Phone
44 20 7495 2379
Country
GB
Employee
8
IPO Date
May 17, 2022
Summary
CIK
0001849296
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
679345108
ISIN
US6793451088
Country
GB
Price
1.4
Beta
-3.15
Volume Avg.
169.7k
Market Cap
46.53M
Shares
-
52-Week
0.92-3.25
DCF
0.1
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.3
P/B
-
Website
https://www.okyopharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest OKYO News
It looks like there's no news available.
